Full Press Release Details
Bio, Inc. Announces Company's CSO Dr. Mark Lowdell to Co-Host the "NK Cells in Solid Tumors" Workshop at Innate Killer
Company also Plans on Sharing INKmune Patient Case Studies
Raton, Florida, March 30, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) ("INMB" or "the
Company"), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune
system to fight disease, is pleased to announce the Company's Chief Scientific Officer Dr. Lowdell will be leading a workshop on
the role of natural killer (NK) cells in the treatment of solid tumors. The presentation, titled, "Challenges of NK Immunotherapy
of Solid Tumors: Potentiation of intra-tumoral NK Function," is part of the 7th Innate Killer Summit being held
in San Diego from March 30 to April 1.
Innate Killer Summit conference is widely viewed as one of the most important meetings in translational NK cell immunotherapy.
cells are established as an important part of the anti-tumor immune response, but their clinical application has been difficult, especially
in solid tumors," said Dr. Lowdell, CSO of INmune Bio. "This workshop strives to understand why NK cell therapies fail in
solid tumors and how we can improve the therapeutic response and practicality of NK therapeutics. Our aim is to make NK cells effective
in the fight against cancer so patients will benefit."
Lowdell has identified several of the problems to be discussed, and addressed:
Lowdell will further discuss INKmune Patient Case Studies:
the last Innate Killer Summit, INmune has treated three patients with INKmune and will share these results with the NK community
at the conference. The first MDS patient, a 74-year-old man, remains stable 9 months after therapy. Updated results at the lowest dose
cohort of INKmune treatment at day 119 show:
21-year-old female with relapsed AML and mixed chimerism after stem cell transplant reestablished 100% donor chimerism after INKmune
therapy. She remains under close observation as an out-patient more than 6 months after INKmune therapy. The third patient, a
young man with AML who failed two transplants remains desperately ill. "The Innate Killer Summit is the best place to share our
data and discuss our pre-clinical and clinical results with the community of scientists developing NK-based immunotherapies", said
is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune
system to fight disease. INmune Bio has two product platforms that are both in clinical trials. The DN-TNF product platform utilizes
dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target
of many diseases. DN-TNF is in clinical trials to determine if it can treat cancer (INB03 ), Mild Alzheimer's disease, Mild
Cognitive Impairment and treatment resistant depression (XProTM). The Natural Killer Cell Priming Platform includes INKmune
aimed at priming the patient's NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio's product
platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic
inflammation. To learn more, please visit www.inmunebio.com.
trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press
release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities
Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may constitute forward-looking
statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained
herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain
events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and
uncertainties. INB03 , XPro1595, and INKmune are still in clinical trials or preparing to start clinical trials and have
not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. The factors
that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties
relating to the Company's ability to produce more drug for clinical trials; the availability of substantial additional funding
for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization;
and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies.
These and other factors are identified and described in more detail in the Company's filings with the Securities and Exchange Commission,
including the Company's Annual Report on Form 10-K, the Company's Quarterly Reports on Form 10-Q and the Company's
Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event
or circumstance that may arise after the date of this release.